Kidder Stephen W reduced its stake in shares of Johnson & Johnson (NYSE:JNJ) by 1.4% during the third quarter, Holdings Channel reports. The fund owned 116,090 shares of the company’s stock after selling 1,679 shares during the period. Johnson & Johnson makes up 5.5% of Kidder Stephen W’s investment portfolio, making the stock its largest position. Kidder Stephen W’s holdings in Johnson & Johnson were worth $13,712,000 as of its most recent SEC filing.
Several other large investors also recently added to or reduced their stakes in JNJ. Tuttle Tactical Management LLC acquired a new position in shares of Johnson & Johnson during the second quarter worth approximately $103,000. Lenox Wealth Management Inc. boosted its position in Johnson & Johnson by 24.3% in the second quarter. Lenox Wealth Management Inc. now owns 972 shares of the company’s stock worth $118,000 after buying an additional 190 shares during the period. Hefty Wealth Partners boosted its position in Johnson & Johnson by 559.4% in the third quarter. Hefty Wealth Partners now owns 1,121 shares of the company’s stock worth $132,000 after buying an additional 951 shares during the period. Taylor Wealth Management Partners boosted its position in Johnson & Johnson by 1.3% in the second quarter. Taylor Wealth Management Partners now owns 1,505 shares of the company’s stock worth $183,000 after buying an additional 20 shares during the period. Finally, Diker Management LLC purchased a new position in Johnson & Johnson during the second quarter worth about $206,000. Institutional investors and hedge funds own 65.30% of the company’s stock.
Shares of Johnson & Johnson (NYSE:JNJ) opened at 115.24 on Monday. Johnson & Johnson has a 52-week low of $101.65 and a 52-week high of $126.07. The company has a 50-day moving average of $114.45 and a 200 day moving average of $117.02. The company has a market capitalization of $313.51 billion, a PE ratio of 19.43 and a beta of 0.74.
Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, January 24th. The company reported $1.58 earnings per share for the quarter, topping the consensus estimate of $1.56 by $0.02. The firm earned $18.10 billion during the quarter, compared to the consensus estimate of $18.28 billion. Johnson & Johnson had a net margin of 22.78% and a return on equity of 25.61%. The company’s revenue was up 1.7% on a year-over-year basis. During the same quarter last year, the company earned $1.44 earnings per share. Analysts predict that Johnson & Johnson will post $7.04 earnings per share for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 14th. Stockholders of record on Tuesday, February 28th will be paid a $0.80 dividend. The ex-dividend date is Friday, February 24th. This represents a $3.20 annualized dividend and a dividend yield of 2.78%. Johnson & Johnson’s payout ratio is 54.42%.
A number of research analysts have recently issued reports on the stock. Zacks Investment Research cut shares of Johnson & Johnson from a “hold” rating to a “sell” rating in a research note on Tuesday, January 3rd. Goldman Sachs Group, Inc. (The) cut their target price on shares of Johnson & Johnson from $120.00 to $115.00 and set a “neutral” rating for the company in a research note on Wednesday, January 25th. Wells Fargo & Company cut shares of Johnson & Johnson from an “outperform” rating to a “market perform” rating and lifted their target price for the company from $112.28 to $112.80 in a research note on Thursday, January 26th. Jefferies Group LLC reiterated a “hold” rating and issued a $107.00 target price on shares of Johnson & Johnson in a research note on Tuesday, December 20th. Finally, Vetr cut shares of Johnson & Johnson from a “buy” rating to a “hold” rating and set a $119.60 target price for the company. in a research note on Tuesday, November 1st. One research analyst has rated the stock with a sell rating, twelve have given a hold rating and eight have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average price target of $122.92.
About Johnson & Johnson
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).